Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 760 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: lymph node Clear all
Active, not recruiting Phase 2 Interventional Results available

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

NCT01723774
View directory record Official record
Conditions
Breast Neoplasms
Interventions
PD0332991, Anastrozole, Goserelin, Surgery (standard of care), Tumor biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
4
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Phase 1 Interventional

Near-Infrared Fluorescent Sentinel Lymph Node Mapping for Breast Cancer

NCT00721370
View directory record Official record
Conditions
Breast Cancer
Interventions
NIR imaging system
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2013 · Synced Oct 30, 2026, 11:42 AM EDT
Recruiting Phase 2 Interventional

Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

NCT06160791
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytoses
Interventions
Ruxolitinib, Etoposide, Dexamethasone, Non-interventional Imaging, Research Biopsy, Biospecimen Collection
Drug · Procedure
Lead sponsor
Jerry Lee, MD, MSc, MPhil
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
Irvine, California • Sacramento, California • San Diego, California + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer

NCT03107182
View directory record Official record
Conditions
HPV-Related Squamous Cell Carcinoma, HNSCC
Interventions
nab-paclitaxel, Carboplatin, Nivolumab, Cisplatin, Hydroxyurea, 5-FU, Dexamethasone, Famotidine, Diphenhydramine, Paclitaxel, Transoral robotic surgery (TORS), Adjuvant RT, Chemoradiotherapy
Drug · Procedure · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Not applicable Interventional Results available

Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer

NCT01040624
View directory record Official record
Conditions
Prostate Cancer
Interventions
> 15% risk of + LN
Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 30, 2026, 11:42 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Microbiome in Colorectal Cancer Onset and Progression

NCT05368688
View directory record Official record
Conditions
Colorectal Cancer, Tumor, CRC, GI Cancer, Gastrointestinal Cancer
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
50 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 30, 2026, 11:42 AM EDT
Not listed Phase 2 Interventional Results available

Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva

NCT01595061
View directory record Official record
Conditions
Stage III Vulvar Cancer AJCC v7, Stage IIIA Vulvar Cancer AJCC v7, Stage IIIB Vulvar Cancer AJCC v7, Stage IIIC Vulvar Cancer AJCC v7, Stage IVA Vulvar Cancer AJCC v7, Vulvar Squamous Cell Carcinoma
Interventions
Cisplatin, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy, Therapeutic Conventional Surgery
Drug · Radiation · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
193
States / cities
Birmingham, Alabama • Anchorage, Alaska • Burbank, California + 130 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Phase 3 Interventional

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

NCT03924856
View directory record Official record
Conditions
Bladder Cancer
Interventions
Pembrolizumab, Gemcitabine, Cisplatin, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Placebo
Drug · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
907 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
24
States / cities
La Jolla, California • Santa Monica, California • Washington D.C., District of Columbia + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer

NCT00854789
View directory record Official record
Conditions
Breast Cancer
Interventions
E75 + GM-CSF vaccine
Biological
Lead sponsor
COL George Peoples, MD, FACS
Federal
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Windber, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies

NCT00857389
View directory record Official record
Conditions
Stem Cell Transplantation, Leukemia, Lymphoma
Interventions
Thiotepa, Clofarabine, Busulfan, Allogeneic Stem Cell Transplantation, Thymoglobulin (ATG), G-CSF (Filgrastim), Tacrolimus, Methotrexate, Cyclophosphamide, Mesna
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Phase 2 Interventional

Intraoperative Pathological Evaluation for Surgical Treatment & Staging for Endometrial Cancer

NCT01512810
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Lymphadenectomy
Procedure
Lead sponsor
Frederick R. Ueland, M.D.
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 30, 2026, 11:42 AM EDT
Recruiting Phase 1 Interventional

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

NCT05076760
View directory record Official record
Conditions
Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer
Interventions
MEM-288 Intratumoral Injection, Nivolumab, Docetaxel
Biological · Drug
Lead sponsor
Memgen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
2
States / cities
Tampa, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Phase 1 Interventional

Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer

NCT02036918
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sipuleucel-T, Lymph Node Biopsy
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 30, 2026, 11:42 AM EDT
Active, not recruiting Not applicable Interventional

Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma

NCT02537548
View directory record Official record
Conditions
Lymphadenopathy, Stage I Testicular Seminoma, Stage II Testicular Seminoma
Interventions
Laboratory Biomarker Analysis, Retroperitoneal Lymph Node Dissection
Other · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
16 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
14
States / cities
Loma Linda, California • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Feasibility of One-Step Sentinel Lymph Node (SLN) Biopsy With Radiolabeled Methylene Blue (IND 70,627)

NCT00784849
View directory record Official record
Conditions
Breast Cancer
Interventions
Methylene blue
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
2
States / cities
Lafayette, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 30, 2026, 11:42 AM EDT
Recruiting Phase 1 Interventional

IL-8 Receptor Modified Patient-Derived Activated CD70 CAR T Cell Therapy in Adults With Brain Metastases

NCT07569263
View directory record Official record
Conditions
Brain Metastases
Interventions
Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells, CD70 IHC assay
Biological · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2044
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 11:42 AM EDT
Terminated No phase listed Observational

Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection

NCT05236387
View directory record Official record
Conditions
Breast Cancer
Interventions
99m Tc-TM
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 30, 2026, 11:42 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

NCT03809000
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy, Enzalutamide, Bicalutamide, GnRH analog
Radiation · Drug
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
106
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Not applicable Interventional Results available

Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging

NCT01673022
View directory record Official record
Conditions
Endometrial Cancer, Cervical Cancer
Interventions
IC Green
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
7
States / cities
Mobile, Alabama • Indianapolis, Indiana • Edgewood, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 30, 2026, 11:42 AM EDT
Recruiting No phase listed Observational

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

NCT04022616
View directory record Official record
Conditions
Breast Cancer
Interventions
Specimen collection
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 30, 2026, 11:42 AM EDT
Terminated Not applicable Interventional

Surgical Versus Non-surgical Staging of Lung Cancer

NCT01117714
View directory record Official record
Conditions
Lung Cancer
Interventions
Integrated Staging for Early Detection of Metastases in Lung Cancer
Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Jacksonville, Florida • Rochester, Minnesota • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 30, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer

NCT00057785
View directory record Official record
Conditions
Head and Neck Cancer, Oral Complications of Radiation Therapy, Radiation Toxicity
Interventions
cisplatin, fluorouracil, Intensity modulated radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
17
States / cities
Birmingham, Alabama • Davis, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 30, 2026, 11:42 AM EDT
Completed No phase listed Observational

Survey on Lymphedema After Sentinel Lymph Node Biopsy in People With Cervical or Vulvar Cancer

NCT05255393
View directory record Official record
Conditions
Cervical Cancer, Vulvar Cancer
Interventions
Questionnaires
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 30, 2026, 11:42 AM EDT
Recruiting Phase 2 Interventional

A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information

NCT07621614
View directory record Official record
Conditions
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Cutaneous Melanocytic Neoplasm, Cutaneous Melanoma, Cutaneous Spitz Melanocytoma, Cutaneous Spitz Melanoma
Interventions
Biospecimen Collection, Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Re-Excision, Sentinel Lymph Node Biopsy, Ultrasound Imaging, Wide Local Excision
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 25 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
13
States / cities
Oakland, California • Wilmington, Delaware • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 30, 2026, 11:42 AM EDT